Koyfin Home > Directory > Health Care > Antares Pharma > Long-term Debt / Equity

Antares Pharma Long-term Debt / Equity Chart (ATRS)

Antares Pharma annual/quarterly Long-term Debt / Equity from 2001 to 2018.
  • Antares Pharma Long-term Debt / Equity for the quarter ending December 12, 2018 was $64m a -36.97% decrease of -24m year over year
  • Antares Pharma Long-term Debt / Equity for the last 12 months ending December 12, 2018 was $64m a -36.97% decrease of -24m year over year
  • Antares Pharma Annual Long-term Debt / Equity for 2018 was $64m a -15.02% decrease of -10m from 2017
  • Antares Pharma Annual Long-term Debt / Equity for 2017 was $74m a 58.27% increase of 43m from 2016
  • Antares Pharma Annual Long-term Debt / Equity for 2008 was $31m a 13.77% increase of 4m from 2007
Other Ratios Metrics:
  • Antares Pharma Total Debt / Capital for the quarter ending December 12, 2018 was $39m a -19.64% decrease of -8m year over year
  • Antares Pharma Other Liabilities for the quarter ending September 09, 2018 was $0m a 0.00% decrease of 0m year over year
  • Antares Pharma Total Debt / Equity for the quarter ending December 12, 2018 was $64m a -36.97% decrease of -24m year over year
View Chart On Koyfin

Quarterly ATRS Long-term Debt / Equity Data

12/2018$64m
09/2018$103m
06/2018$101m
03/2018$88m
12/2017$74m
09/2017$69m
06/2017$61m
09/2009$0m
06/2009$29m
03/2009$32m

Annual ATRS Long-term Debt / Equity Data

2018$64m
2017$74m
2008$31m
2007$27m
2002$5m
2001$1m